Skip to main content English

Klinische Forschung

 

Prof. Philipp Staber ist Studienleiter für derzeit 20 klinische Studien:

Chronisch lymphatische Leukämie (CLL):

  • CC-122-CLL-001 (Celgene): R/R CLL; Phase 1-2, safety, pharmacokinetics, efficacy
  • MOR208C205 (MorphoSys AG): R/R CLL after BTK; Phase 1-2 (national PI)
  • CLL13 / DCLSGCLL13001 (GCLLSG): de novo CLL, Phase 3
  • CLL RT1: Richter’s Transformation; Phase 2 (national PI)
  • CLL17 : (GCLLSG): de novo CLL, Phase 3 (national PI)
  • CLL16 : (GCLLSG): de novo CLL high risk, Phase 2 (national PI)
  • CC-99282-CLL-00: R/R CLL; (Celgene) Phase 1-2, + pharmacokinetics, (institutional PI)

T-Zell-Lymphome (T-NHL):

  • Ro-CHOP / NCT01796002 (Lysarc): de novo PTCL, Phase 3
  • ORACLE (Lysarc): de novo AITL, Phase 3; Start Q9 2019 (national PI)
  • VIT study (AbbVie, ITPLLSG): R/R T-PLL, Phase 2; Start Q4 2019 (international PI)
  • AGMT-PTCL-Registry (MUV): Austrian registry and biobank of T-cell lymphomas

B-Zell-Lymphome (B-NHL):

  • GO39942 / R-CHP + Polatuzumab Vedotin (Roche): de novo DLBCL, Phase 3
  • Chronos 3 / 17067 (Bayer): R/R indolent B-NHL including WM, Phase 2 (national PI)
  • 1st MIND (MorphoSys AG): de novo DLBCL, Phase 1b, Start Q1 2020 (national PI)
  • Front-Mind (MorphoSys AG): DLBCL, phase 3, placebo-controlled trial
  • ImbruVeRCHOP in-1st (Charitè Berlin): DLBCL, Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab

NHL/Leukämie:

  • EXALT (MUV): 2nd line R/R hem. malignancies, Phase 1 / 2
  • EXALT-2 (Roche, MUV): >2nd line R/R hem. malignancies; Phase 3; Q2 2019
  • CAR-T:    
  • Phase 3, Axicabtagene Ciloleucel in High-Risk Large B-Cell Lymphoma (ZUMA-23)
  • Phase 2, Brexucabtagene Autoleucel Basket Study in Rare B-cell lymphoma (ZUMA-25)